Company intelligence / Profile preview

Genmab

Ownership: Private
Employees: ~2000
Development stage: Other

Overview

Genmab is a leading international biotechnology company specializing in the discovery and development of differentiated human antibody therapies for cancer and other serious diseases. The company has eight approved therapies—including Darzalex (daratumumab), Kesimpta (ofatumumab), Tepezza (teprotumumab), Tivdak (tisotumab vedotin), EPKINLY—and several proprietary technology platforms. Recent regulatory milestones include approvals for Tivdak in advanced cervical cancer and EPKINLY for follicular lymphoma in Japan. Clinical results have established its antibodies as standards of care across multiple indications.

Therapeutic areas: OncologyEndocrinologyNeurologyHematology
Modalities: Monoclonal antibodyAntibody-drug conjugateBispecific monoclonal antibodySmall moleculeOther biologics
Industry: Biotech

Partnerships

NovartisJohnson & JohnsonAbbVieSeagenBioNTech

Beyond the preview

Go deeper on Genmab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genmab.

Explore the full profile